Zelemiq Life Science Limited secures investment to accelerate development of myRipple® non-invasive metabolic monitoring technology

Zelemiq Life Science Limited, the innovator behind the myRipple® metabolic monitoring platform, today announced the successful completion of a new £200,000 seed funding round. The investment, secured through the FounderCatalyst platform, will be used to accelerate the myRipple®  product development, further validate the solution for the elite sports market, with a specific focus on real-time lactate monitoring, and initiate sales & marketing.

“Zelemiq completed their funding round using the FounderCatalyst platform, all for a fixed fee of £1,495, a very exciting phase of growth lies ahead.”

Max Heal, CEO at FounderCatalyst. 

“We are shifting the paradigm from ‘snapshots’ to a continuous ‘live feed’ of metabolic performance,”. “With this investment, we are well-positioned to bring lab-grade metabolic insight directly to the coach’s screen in real-time, helping athletes perform at their peak without the disruption of invasive testing.”
Rod Lane, Co-Founder and CEO of Zelemiq

Zelemiq is the developer of myRipple®, a groundbreaking, non-invasive wearable device that provides a continuous “live feed” of an athlete’s metabolic state. By utilizing patent-protected low-frequency bioimpedance spectroscopy, myRipple® captures high-fidelity physiological signals that were previously considered inaccessible, offering elite athletes and their coaches an unprecedented view of their internal metabolic engine. myRipple® can monitor lactate profiles with plans to monitor glucose and hydration in the near future.

The myRipple® platform will empower elite athlete programs to move beyond simple heart rate monitoring. By capturing a view of lactate accumulation and clearance in real-time, myRipple® is setting a new standard for metabolic performance monitoring.

Founded by Isaac Watson and Rodney Lane, Zelemiq has deep expertise across industrial control, agriculture, IoT, and medtech to empower clients to innovate confidently and compliantly. This latest investment marks a pivotal milestone as the company transitions its flagship myRipple® technology from successful field trials into broader adoption.

For more information about Zelemiq Life Science Limited and the myRipple® platform, please visit myripple.co.uk